IV Triamcinolone and Ozurdex: The Evidence.

The article mentions that intravitreal triamcinolone acetonide and dexamethasone implant (Ozurdex) were approved by the U.S. Food and Drug Administration (FDA) for treatment of macular edema due to branch retinal vein occlusion (BRVO) or central retinal vein occlusion (CRVO). It cites the dampening effects of vascular endothelial growth factors (VEGF), which decreases the formation of macular edema. It mentions that dexamethasone reduce vascular permeability and leukocyte accumulation.